Rho激酶抑制剂对慢性肺源性心脏病患者肺动脉高压的影响及其作用机制探讨  

Effect of Rho kinase inhibitor on pulmonary hypertension in patients with chronic pulmonary heart disease and its mechanism

作　　者：帖永新[1] 徐震[1] 

机构地区：[1]河南省新乡市中心医院呼吸内科,453000

出　　处：《中国实用医刊》2014年第1期17-19,共3页Chinese Journal of Practical Medicine

摘　　要：目的观察Rho激酶抑制剂（法舒地尔）对慢性肺源性心脏病患者肺动脉高压的影响，并探讨其作用机制。方法将60例慢性肺源性心脏病患者随机分为治疗组和对照组各30例，治疗组在常规治疗基础上加用法舒地尔注射液，对照组给予常规治疗。结果两组患者治疗后与治疗前肺动脉收缩压（SPAP）、肺动脉平均压（MPAP）比较均有显著下降，差异有统计学意义（P〈0．01），治疗后两组SPAP、MPAP比较差异有统计学意义（P〈0．05）。结论Rho激酶抑制剂（法舒地尔）可明显降低慢性肺源性心脏病患者肺动脉高压，改善肺血管重构。对慢性肺源性心脏病患者的治疗具有积极意义。Objective To observe the effect of Rho kinase inhibitor （fasudil） on pulmonary hy- pertension patients with chronic pulmonary heart disease, and investigate its mechanism. Methods Six- ty patients with chronic pulmonary heart disease were randomly divided into treatment group and control group, the patients in treatment group were given fasudit injection based on regtllar treatment, the pa- tients in the control group were given routine treatment. Results After treatment, compared with before treatment, SPAP and MPAP were significantly decreased of the two groups, the differences were statisti- cally significant （P 〈0. 01 ）. After treatment, differences of SPAP, MPAP between the two groups were significant （P 〈 0. 05 ）. Conclusions Rho kinase inhibitor （fasudil） can significantly reduce pulmoiaary hypertension of chronic pulmonary heart disease, ameliorate pulmonary vascular remodeling, and has pos- itive significance for the treatment of patients with chronic pulmonary heart disease.

关 键 词：慢性肺源性心脏病 肺动脉高压 RHO激酶抑制剂 

分 类 号：R541.5[医药卫生—心血管疾病]